Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCCR PK Study in Healthy Volunteers
NCT02893618Phase 2Unknown
- Sponsor
- Essentialis, Inc.
- Start
- Jul 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of diazoxide in Prader-Willi syndrome (PWS) (5 arms), sponsored by Essentialis, Inc. Primary endpoints: Maximum Plasma Concentration up to 24 hours and Area Under the Curve 0-24h. Status: unknown.
02
Drugs
diazoxide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT02893618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893618.